Matinas Biopharma Holdings Inc (AMEX:MTNB) shares, rose in value, with the stock price down by -35.00% to the previous day’s close as strong demand from buyers drove the stock to $0.23.
Actively observing the price movement in the last trading, the stock closed the session at $0.35. Referring to stock’s 52-week performance, its high was $0.89, and the low was $0.11. On the whole, MTNB has fluctuated by -15.46% over the past month.
With the market capitalization of Matinas Biopharma Holdings Inc currently standing at about $49.48 million, investors are eagerly awaiting this quarter’s results, scheduled for May 08, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.03, which is expected to increase to -$0.03 for fiscal year -$0.11 and then to about -$0.1 by fiscal year 2025.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MTNB’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MTNB currently trading nearly -19.07% and -7.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.02, while the 7-day volatility ratio is showing 19.75% which for the 30-day chart, stands at 15.20%. Furthermore, Matinas Biopharma Holdings Inc (MTNB)’s beta value is 1.52, and its average true range (ATR) is 0.05.
A comparison of Matinas Biopharma Holdings Inc (MTNB) with its peers suggests the former has fared considerably weaker in the market. MTNB showed an intraday change of -35.00% in last session, and over the past year, it shrunk by -51.60%%.
Data on historical trading for Matinas Biopharma Holdings Inc (AMEX:MTNB) indicates that the trading volumes over the past 10 days have averaged 5.44 million and over the past 3 months, they’ve averaged 1.36 million. According to company’s latest data on outstanding shares, there are 217.26 million shares outstanding.
Nearly 2.92% of Matinas Biopharma Holdings Inc’s shares belong to company insiders and institutional investors own 11.91% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.32 million shares as on Mar 15, 2024, resulting in a short ratio of 1.07. According to the data, the short interest in Matinas Biopharma Holdings Inc (MTNB) stood at 0.61% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 1.2 million. The stock has risen by 5.23% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MTNB stock heading into the next quarter.
